Last updated: October 23, 2026
Elidel, the branded 1% pimecrolimus cream, is a mature topical dermatology product with no meaningful remaining U.S. regulatory exclusivity. Its commercial value has shifted from branded innovation to residual prescription demand, payer coverage, brand recognition, and generic supply. Standalone Elidel revenue is generally not disclosed by current or former owners, so its financial trajectory must be assessed through product lifecycle events, market structure, and company-level dermatology reporting.
What is Elidel and how is it used?
Elidel contains pimecrolimus, a topical calcineurin inhibitor approved for mild-to-moderate atopic dermatitis. The U.S. label covers adults and children aged two years and older who are not adequately responsive to, or cannot tolerate, topical corticosteroids. It is applied twice daily to affected skin and is intended for short-term and intermittent long-term use when appropriate. [1]
Elidel is positioned against:
- Topical corticosteroids
- Tacrolimus ointment, marketed as Protopic
- Crisaborole ointment, marketed as Eucrisa
- Topical ruxolitinib cream, marketed as Opzelura
- Systemic and biologic therapies for moderate-to-severe atopic dermatitis, including dupilumab and tralokinumab
Pimecrolimus is a small-molecule immunomodulator. It is not a biologic and therefore has no biosimilar pathway. Competitive erosion occurs through generic substitution and therapeutic substitution rather than biosimilar entry.
When did Elidel receive FDA approval?
The FDA approved Elidel cream 1% on Dec. 13, 2001. The original sponsor was Novartis Pharmaceuticals Corporation. [2]
| Milestone |
Date |
Commercial effect |
| FDA approval for atopic dermatitis |
Dec. 13, 2001 |
Created U.S. branded market |
| Pediatric labeling and postmarketing developments |
2000s |
Expanded use in children aged two and older |
| FDA boxed warning added |
March 2005 |
Increased prescribing and payer friction |
| Core patent term expiration |
Primarily mid-to-late 2010s |
Removed meaningful composition-of-matter protection |
| Generic pimecrolimus availability |
2010s onward |
Increased substitution and price pressure |
| Current market position |
Mature product |
Residual brand demand and generic competition |
The 2005 FDA boxed warning addressed a theoretical risk of malignancy associated with topical calcineurin inhibitors. The warning applies to both pimecrolimus and tacrolimus and has remained a commercial consideration in prescribing decisions. [3]
What patents protect Elidel?
Elidel’s original U.S. patent estate centered on pimecrolimus and related ascomycin compounds, with additional protection potentially covering pharmaceutical compositions and treatment methods. The principal commercial barriers have expired.
Core composition patents
U.S. Patent No. 5,985,889 covered ascomycin derivatives, including compounds related to pimecrolimus. Its effective patent term ended in the 2010s. The expiration of this type of core compound protection removed the primary barrier to generic pimecrolimus development.
The original patent estate also included foreign counterparts and related applications. Those rights were subject to national patent-term rules and did not create a durable global exclusivity position after the U.S. core term ended.
Formulation patents
Elidel is a topical cream containing 1% pimecrolimus. Formulation protection was commercially relevant during the branded period, but formulation patents generally provided narrower protection than the underlying compound patent. Once the active ingredient became available for generic development, formulation claims had limited ability to preserve the original branded market.
Generic developers could seek approval using formulations that met FDA requirements without duplicating every aspect of the branded product, provided the products demonstrated pharmaceutical equivalence and bioequivalence or complied with the applicable topical-product standards.
Method-of-use patents
Method-of-use claims for treating atopic dermatitis may have supplemented the patent estate. Their commercial value was limited because:
- The principal indication was already established.
- Generic manufacturers could use skinny-label or carve-out strategies where legally available.
- Atopic dermatitis treatment is not dependent on a single patented clinical protocol.
- The product’s core commercial value derived from the active ingredient and dosage form.
What is the Orange Book status of Elidel?
Elidel’s original U.S. regulatory exclusivity has expired, and the product is exposed to generic competition. FDA Orange Book records are the primary source for current listed patents, exclusivity, therapeutic-equivalence codes, and reference-product information. [4]
The relevant commercial conclusion is that Elidel no longer has the regulatory profile of a protected innovative product:
| Orange Book issue |
Elidel position |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Active composition patent barrier |
Expired or no longer commercially decisive |
| Generic approval pathway |
ANDA pathway |
| Biosimilar pathway |
Not applicable |
| Current brand vulnerability |
High |
The exact list of active patents can change as FDA records are updated. Expired patents do not prevent ANDA approval or routine generic substitution.
When did Elidel lose exclusivity?
Elidel lost practical exclusivity in stages rather than on a single date.
The initial loss occurred when the core patent estate reached the end of its statutory term. The commercial loss accelerated once generic pimecrolimus products received FDA approval and pharmacies and payers gained substitution options.
The 2005 boxed warning also weakened the product’s commercial position before patent expiry. Dermatologists and primary-care physicians could use topical corticosteroids for many patients, while tacrolimus provided a competing topical calcineurin inhibitor. Elidel therefore entered the post-patent period with an established but contested therapeutic role.
How strong is the Elidel patent estate?
The current Elidel patent estate is weak as a barrier to generic entry.
| Patent-strength factor |
Assessment |
| Active ingredient protection |
Low; core protection expired |
| Formulation protection |
Low to moderate historically, low current barrier |
| Method-of-use protection |
Limited practical value |
| Regulatory exclusivity |
Expired |
| Manufacturing complexity |
Low to moderate |
| Generic substitution risk |
High |
| Litigation leverage |
Low absent a currently enforceable blocking patent |
Topical creams can present manufacturing challenges involving particle size, emulsion stability, viscosity, preservative systems, and scale-up consistency. Those issues can delay or complicate approval, but they generally do not create durable exclusivity once several manufacturers have commercialized equivalent products.
Which companies are challenging Elidel?
Elidel has been challenged primarily through the generic ANDA pathway rather than through a high-profile patent litigation campaign in the manner of major small-molecule products with active Orange Book patents.
Generic competitors can enter through:
- ANDA approval for pimecrolimus cream 1%
- Paragraph IV certification if an Orange Book patent is listed and asserted
- Paragraph III certification after patent expiry
- Non-infringement or invalidity positions against listed formulation or use patents
- State-level and payer-driven substitution after approval
Publicly reported litigation has not made Elidel a major current pharmaceutical patent dispute. The central competitive event was the transition from branded prescription demand to generic supply after loss of meaningful exclusivity.
What generic entry risks exist for Elidel?
Generic entry risk is high because the product has the characteristics that support rapid erosion:
- The active ingredient is a well-characterized small molecule.
- The dosage form is a conventional topical cream.
- The indication is established.
- Pediatric use is included in the reference labeling.
- The product has no remaining NCE or pediatric exclusivity.
- Dermatology formularies can encourage substitution.
- Payers have an incentive to use lower-cost alternatives.
The main commercial risk is not a single generic launch. It is cumulative price erosion as several suppliers compete for formulary position and pharmacy shelf access.
Generic launch scenarios
| Scenario |
Likely market effect |
| One approved generic |
Moderate price pressure; brand may retain some prescriptions |
| Two to four generics |
Rapid substitution and lower net prices |
| Broad generic participation |
Brand demand becomes concentrated in coverage exceptions and loyal prescribers |
| Supply disruption |
Temporary branded or authorized-generic recovery |
| New branded topical entrant |
Further loss of clinical share, independent of price |
Generic competition can be slower for topical products than for oral tablets because physicians and pharmacists may be cautious about substituting semisolid products. Even so, the absence of meaningful exclusivity leaves the brand exposed.
What is the FDA regulatory status of Elidel?
Elidel remains an FDA-approved prescription product for atopic dermatitis in patients aged two years and older. The product carries the topical calcineurin inhibitor boxed warning. [1]
The key regulatory constraints are:
- Prescription-only status
- Use in patients aged two years and older
- Short-term and intermittent treatment positioning
- Avoidance of continuous long-term use where not clinically necessary
- Warning regarding potential malignancy risk
- Caution regarding use on infected, malignant, or otherwise compromised skin
The label supports the product’s continued clinical use but does not provide regulatory exclusivity. Its value is therefore commercial and therapeutic, not exclusivity-driven.
How does Elidel compare with Protopic, Eucrisa, and Opzelura?
Elidel competes in a crowded nonsteroidal topical market.
| Product |
Active ingredient |
Dosage form |
Main differentiation |
Exclusivity position |
| Elidel |
Pimecrolimus |
1% cream |
Nonsteroidal calcineurin inhibitor; cream vehicle |
Mature, generic-exposed |
| Protopic |
Tacrolimus |
Ointment |
Stronger topical calcineurin inhibitor positioning |
Generic-exposed |
| Eucrisa |
Crisaborole |
2% ointment |
PDE-4 inhibitor; nonsteroidal |
Branded, later lifecycle |
| Opzelura |
Ruxolitinib |
Cream |
Topical JAK inhibitor; broader dermatology positioning |
Active branded franchise |
| Topical corticosteroids |
Multiple |
Creams, ointments, lotions |
Low cost and broad clinical familiarity |
Mostly generic |
Elidel’s cream vehicle can be attractive to patients who dislike ointments. Its disadvantages include the boxed warning, generic competition, and weaker commercial resources than newer dermatology products.
Protopic generally has stronger recognition among clinicians seeking a topical calcineurin inhibitor, particularly for more persistent or sensitive-area disease. Eucrisa competes through a different mechanism and a nonsteroidal profile. Opzelura competes at the higher-value end of topical nonsteroidal therapy but has its own safety, labeling, access, and reimbursement constraints.
What was Elidel’s financial trajectory?
Elidel’s financial trajectory follows a standard mature-drug lifecycle.
Launch and early growth: 2001 to mid-2000s
The product entered a large atopic dermatitis market with a nonsteroidal mechanism and a cream formulation. Initial commercial growth benefited from demand for alternatives to topical corticosteroids, especially for sensitive skin areas and pediatric patients.
The 2005 boxed warning changed the risk-benefit discussion. The warning did not remove Elidel from the market, but it reduced promotional flexibility and likely constrained first-line use.
Mature branded period: late 2000s to early 2010s
Elidel remained a recognized dermatology brand but faced:
- Protopic competition
- Generic topical corticosteroids
- Physician caution after the boxed warning
- Payer pressure
- Increasingly narrow differentiation from other nonsteroidal topical options
Novartis’s later reporting generally grouped dermatology products within broader portfolio categories rather than disclosing a distinct Elidel revenue line. That limits the ability to establish a reliable standalone annual sales series from public company filings.
Patent erosion and post-generic period: 2010s onward
After loss of core patent protection and approval of generic pimecrolimus, Elidel’s economics changed materially:
- Average selling prices declined.
- Pharmacy substitution increased.
- Brand promotion became less attractive.
- Net sales became more dependent on coverage exceptions and prescriber preference.
- Manufacturing and distribution efficiency became more important than clinical differentiation.
Current financial profile
Elidel should be treated as a low-growth or declining mature prescription asset rather than a strategic innovation product. Its current value is likely concentrated in:
- Residual branded demand
- Markets where generic penetration is incomplete
- Formulary niches
- Authorized distribution arrangements
- Portfolio value for a dermatology-focused company
- Manufacturing or supply relationships
No reliable public source establishes a current standalone global Elidel revenue figure. Company filings that aggregate dermatology sales cannot be used to isolate the product without unsupported allocation assumptions.
Who owns or markets Elidel?
Elidel originated with Novartis. Commercial rights and marketing responsibilities have changed over time by geography and corporate transaction. Novartis’s dermatology portfolio history included transfers and divestitures, and later marketing has involved other dermatology-focused companies in certain markets.
Because rights can differ by territory, ownership should be analyzed separately for:
- United States
- European Union
- Japan
- Canada
- Emerging markets
The commercial owner of a trademark or marketing authorization is not necessarily the owner of every underlying patent or manufacturing right. The relevant diligence documents are current FDA labeling, National Drug Code records, Orange Book entries, corporate annual reports, trademark records, and local marketing-authority databases.
What licensing deals affect Elidel?
The most important licensing issue is territorial commercial control rather than active patent licensing. Mature products such as Elidel may be transferred through:
- Asset sales
- Regional license agreements
- Distribution agreements
- Portfolio acquisitions
- Manufacturing and supply contracts
No current high-value licensing structure is publicly associated with Elidel that would materially change its global market outlook. Any transaction valuation would depend more on cash flow from residual brand demand and supply economics than on exclusivity.
What manufacturing and intellectual-property barriers remain?
Manufacturing is a moderate operational barrier but a weak long-term exclusivity barrier.
A generic pimecrolimus cream must control:
- Active-ingredient uniformity
- Particle size and dispersion
- Emulsion stability
- Rheology and spreadability
- Microbial limits
- Container compatibility
- Stability across storage conditions
- Batch-to-batch performance
These requirements can reduce the number of immediately successful applicants. They do not, by themselves, support premium pricing once multiple approved suppliers are available.
The strongest remaining commercial barriers are operational:
- Reliable supply of pimecrolimus
- FDA-compliant semisolid manufacturing
- Quality-system performance
- Pharmacy contracting
- Payer placement
- Dermatology distribution
What is the outlook for Elidel revenue?
The base case is continued decline in branded revenue, offset by stable residual demand in selected patients and geographies.
| Driver |
Direction |
| Generic substitution |
Negative |
| New branded topical competitors |
Negative |
| Established physician familiarity |
Positive |
| Cream formulation preference |
Positive |
| FDA-approved pediatric use |
Positive |
| Boxed warning |
Negative |
| Lack of exclusivity |
Negative |
| Supply reliability |
Potentially positive |
| Dermatology portfolio ownership |
Potentially positive |
Upside would require a supply disruption among generics, a successful repositioning in a defined patient segment, or a territory where generic penetration remains limited. The probability of a broad global revenue recovery is low without a new formulation, new indication, or materially differentiated delivery system.
Key Takeaways
- Elidel is a mature pimecrolimus cream with FDA approval dating to 2001.
- Its NCE, pediatric, and core patent exclusivity periods have expired.
- Generic entry is the principal commercial threat, not biosimilar competition.
- The product remains clinically relevant but has limited pricing power.
- The 2005 boxed warning weakened positioning against topical corticosteroids and newer nonsteroidal therapies.
- Standalone Elidel revenue is not reliably disclosed in public company filings.
- Current value depends on residual brand demand, geographic rights, payer access, and supply execution.
- The patent estate is commercially weak because composition protection has expired and formulation barriers are limited.
- Elidel compares unfavorably with newer branded dermatology products on growth and exclusivity, but retains advantages in familiarity, cream formulation, and pediatric labeling.
FAQs
Is Elidel still commercially available?
Yes. Elidel remains an FDA-approved prescription treatment for atopic dermatitis, although availability and branding can vary by country and distributor.
Is pimecrolimus cream a generic drug?
Pimecrolimus cream is available as a generic in the United States. Elidel is the original branded reference product.
Does Elidel have patent protection in the United States?
The commercially important U.S. compound patent protection has expired. Any remaining listed rights should be checked in the current FDA Orange Book.
Is Elidel a biologic or biosimilar product?
No. Pimecrolimus is a small-molecule active ingredient. Generic drug rules apply; biosimilar rules do not.
Can Elidel sales recover through a new formulation?
A new formulation could create commercial differentiation and potentially new intellectual-property rights, but it would require clinical, regulatory, manufacturing, and payer support. The existing Elidel cream does not have a strong exclusivity-driven growth outlook.
References
-
U.S. Food and Drug Administration. (2024). Elidel (pimecrolimus) cream, 1% prescribing information. FDA.
-
U.S. Food and Drug Administration. (2001). FDA approves Elidel cream for atopic dermatitis. FDA.
-
U.S. Food and Drug Administration. (2005). FDA public health advisory: Elidel and Protopic. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Patent and Trademark Office. (1999). U.S. Patent No. 5,985,889: Ascomycin derivatives. USPTO.
